Indivior PLC Net Income Over Time
| INDV Stock | 34.01 0.55 1.64% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Indivior PLC Performance and Indivior PLC Correlation. What growth prospects exist in Biotechnology sector? Can Indivior capture new markets? Factors like these will boost the valuation of Indivior PLC. Market participants price Indivior higher when confident in its future expansion prospects. Valuation analysis balances hard financial data with qualitative growth assessments. While each Indivior PLC valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Quarterly Earnings Growth 1.063 | Earnings Share 0.98 | Revenue Per Share | Quarterly Revenue Growth 0.023 | Return On Assets |
Understanding Indivior PLC Ordinary requires distinguishing between market price and book value, where the latter reflects Indivior's accounting equity. The concept of intrinsic value - what Indivior PLC's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Market sentiment, economic cycles, and investor behavior can push Indivior PLC's price substantially above or below its fundamental value.
Please note, there is a significant difference between Indivior PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if Indivior PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Indivior PLC's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Indivior PLC Ordinary and related stocks such as Lantheus Holdings, Supernus Pharmaceuticals, and ACADIA Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LNTH | (137.3 M) | (137.3 M) | (42 M) | (61.6 M) | (3.6 M) | (14.7 M) | 26.8 M | 123.4 M | 40.5 M | 31.7 M | (13.5 M) | (71.3 M) | 28.1 M | 326.7 M | 312.4 M | 359.3 M | 377.3 M |
| SUPN | (17.3 M) | 56 M | (46.3 M) | (92.3 M) | 19.9 M | 14 M | 91.2 M | 57.3 M | 111 M | 113.1 M | 127 M | 53.4 M | 60.7 M | 1.3 M | 73.9 M | 84.9 M | 89.2 M |
| ACAD | (10.2 M) | (22.8 M) | (20.8 M) | (37.9 M) | (92.5 M) | (164.4 M) | (271.4 M) | (289.4 M) | (245.2 M) | (235.3 M) | (281.6 M) | (167.9 M) | (216 M) | (61.3 M) | 226.5 M | 203.8 M | 214 M |
| AMRX | 176.9 M | 176.9 M | 176.9 M | 176.9 M | 176.9 M | 169.5 M | 207.4 M | 167.6 M | (169.7 M) | (361.9 M) | 91.1 M | 10.6 M | (130 M) | (84 M) | (116.9 M) | (105.2 M) | (99.9 M) |
| HNGE | (108.1 M) | (108.1 M) | (108.1 M) | (108.1 M) | (108.1 M) | (108.1 M) | (108.1 M) | (108.1 M) | (108.1 M) | (108.1 M) | (108.1 M) | (108.1 M) | (108.1 M) | (108.1 M) | (11.9 M) | (13.7 M) | (14.4 M) |
| ADMA | (29.7 M) | (26.5 K) | (7.3 M) | (15.5 M) | (16.8 M) | (18 M) | (19.5 M) | (43.8 M) | (65.7 M) | (48.3 M) | (75.7 M) | (71.6 M) | (65.9 M) | (28.2 M) | 197.7 M | 227.3 M | 238.7 M |
| PRAX | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (35.5 M) | (61.8 M) | (166.9 M) | (213.1 M) | (123.3 M) | (182.8 M) | (164.5 M) | (172.8 M) |
| CRNX | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (9.2 M) | (27.1 M) | (49.5 M) | (72.9 M) | (106.7 M) | (160 M) | (214.5 M) | (298.4 M) | (268.6 M) | (255.1 M) |
| VKTX | (444) | (444) | (444) | (146.2 K) | (21.9 M) | (23.4 M) | (14.7 M) | (20.6 M) | (22.1 M) | (25.8 M) | (39.5 M) | (55 M) | (68.9 M) | (85.9 M) | (110 M) | (99 M) | (94 M) |
| OPCH | (31.8 M) | 7.9 M | 64.7 M | (69.7 M) | (147.5 M) | (300.1 M) | (42.8 M) | (64.2 M) | (6.1 M) | (75.9 M) | (8.1 M) | 139.9 M | 150.6 M | 267.1 M | 211.8 M | 243.6 M | 255.8 M |
Indivior PLC Ordinary and related stocks such as Lantheus Holdings, Supernus Pharmaceuticals, and ACADIA Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Indivior PLC Ordinary financial statement analysis. It represents the amount of money remaining after all of Indivior PLC Ordinary operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Indivior PLC Ordinary | INDV |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 10710 Midlothian Turnpike, |
| Exchange | NASDAQ Exchange |
null 34.01
Additional Tools for Indivior Stock Analysis
When running Indivior PLC's price analysis, check to measure Indivior PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indivior PLC is operating at the current time. Most of Indivior PLC's value examination focuses on studying past and present price action to predict the probability of Indivior PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indivior PLC's price. Additionally, you may evaluate how the addition of Indivior PLC to your portfolios can decrease your overall portfolio volatility.